The Daily Biotech Pulse: Athira CEO Resigns Over Doctored Research, Merck’s Keytruda Snags First Approval For Breast Cancer In Europe, Minerva And Xilio IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours.
What 10 Analyst Ratings Have To Say About Protagonist Therapeutics
Analysts have provided the following ratings for Protagonist Therapeutics (NASDAQ:PTGX) within the last quarter:
10 Biggest Price Target Changes For Wednesday
MKM Partners raised the price target on Continental Resources, Inc. (NYSE: CLR) from $47 to $54. Continental Resources shares fell 1.3% to $53.03 in pre-market trading.
JMP Securities Maintains Market Outperform on Protagonist Therapeutics, Raises Price Target to $60
JMP Securities analyst Gobind Singh maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Market Outperform and raises the price target from $47 to $60.
Benzinga Pro’s Top 5 Stocks To Watch For Tuesday, Oct. 12, 2021: RRD, XPO, NTRB, OCGN, ZNGA
Today's 5 Stock Ideas:
R. R. Donnelley (RRD) - Shares were up 25% Tuesday morning following a Bloomberg report that suggested Chatham has offered to buy the remainder of R. R. Donnelley for $7.50 per
JP Morgan Upgrades Protagonist Therapeutics to Overweight, Announces $55 Price Target
JP Morgan analyst Anupam Rama upgrades Protagonist Therapeutics (NASDAQ:PTGX) from Neutral to Overweight and announces $55 price target.
SVB Leerink Maintains Outperform on Protagonist Therapeutics, Raises Price Target to $50
SVB Leerink analyst Joseph Schwartz maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Outperform and raises the price target from $35 to $50.